Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

Published

FOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September.

2023 Wells Fargo Healthcare Conference Location: Encore Boston Harbor, Boston, MAFormat: 1x1 Investor Meetings on Thursday, September 7

H.C. Wainwright 25th Annual Global Investment ConferenceLocation: Lotte New York Palace Hotel, New York, NY Format: Fireside Chat on Monday, September 11 at 11:30am ET

A live webcast of the Fireside Chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, NASH and obesity. Terns’ pipeline includes two clinical stage development programs including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/- an FXR agonist), and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Contacts for Terns

InvestorsMark Vignolainvestors@ternspharma.com

MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com

Primary Logo

Source: Terns Pharmaceuticals, Inc.

In This Story

TERN